Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 5(64), 2020

DOI: 10.1128/aac.02394-19

Links

Tools

Export citation

Search in Google Scholar

An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment

Journal article published in 2020 by Jose Francis, Karen I. Barnes ORCID, Lesley Workman, Tamara Kredo, Lasse S. Vestergaard, Richard M. Hoglund, Pauline Byakika-Kibwika, Mohammed Lamorde, Stephen I. Walimbwa ORCID, Ifeyinwa Chijioke-Nwauche, Colin J. Sutherland ORCID, Concepta Merry, Kimberley K. Scarsi, Nyagonde Nyagonde, Martha M. Lemnge and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Treating malaria in HIV-coinfected individuals should consider potential drug-drug interactions. Artemether-lumefantrine is the most widely recommended treatment for uncomplicated malaria globally. Lumefantrine is metabolized by CYP3A4, an enzyme that commonly used antiretrovirals often induce or inhibit. A population pharmacokinetic meta-analysis was conducted using individual participant data from 10 studies with 6,100 lumefantrine concentrations from 793 nonpregnant adult participants (41% HIV-malaria-coinfected, 36% malaria-infected, 20% HIV-infected, and 3% healthy volunteers).